VACC Vaccitech plc

17
+0.23  (+1%)
Previous Close 16.77
Open 17.99
52 Week Low 12.25
52 Week High 17.87
Market Cap $579,093,865
Shares 34,064,345
Float 34,064,345
Enterprise Value $574,357,789
Volume 71,376
Av. Daily Volume 0
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
VTP-500
Middle East respiratory syndrome (MERS)
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
VTP-300 (HBV001)
Hepatitis B and healthy volunteers
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
VTP-300 (HBV002)
Hepatitis B
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
VTP-200
Human papillomavirus (HPV)
Phase 1/2
Phase 1/2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
VTP-400
Shingles
Phase 1
Phase 1
Phase 1 trial to to commence 1H 2022.
VTP-600 and pembroluzimab
Non-small cell lung cancer
Phase 1/2
Phase 1/2
Phase 1/2 trial to commence 2Q 2021.
VTP-850
Prostate cancer
Phase 1/2
Phase 1/2
Phase 1/2 trial to commence 1Q 2022.
AZD1222
COVID-19 vaccine
Phase 3
Phase 3
Phase 3 data exhibited 70% efficacy (90% and 60% across two dosing regimens) - UK and Brazil trial. Data from U.S. trial noted 76% efficacy rate - March 24, 2021.

Latest News

  1. OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the closing of its initial public offering in the United States of 6,500,000 American Depositary Shares ("ADSs") representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS. The gross proceeds from the offering were approximately $110.5 million. Vaccitech's ordinary shares began trading on the Nasdaq Global Market in the U.S. under the ticker symbol "VACC" on April 30, 2021. All ADSs sold in the offering were offered…

    OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the closing of its initial public offering in the United States of 6,500,000 American Depositary Shares ("ADSs") representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS. The gross proceeds from the offering were approximately $110.5 million. Vaccitech's ordinary shares began trading on the Nasdaq Global Market in the U.S. under the ticker symbol "VACC" on April 30, 2021. All ADSs sold in the offering were offered by Vaccitech.

    Morgan Stanley, Jefferies, Barclays and William Blair acted as joint book-running managers for the offering. H.C. Wainwright & Co. acted as lead manager for the offering.

    The Registration Statement on Form S-1 relating to the proposed sale of these securities was filed with the U.S. Securities and Exchange Commission and was declared effective on April 29, 2021.

    The offering of ADSs was made only by means of a prospectus, copies of which may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at ; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at ; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at  or telephone at 1-888-603-5847; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at 

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Vaccitech plc

    Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company's proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

    Vaccitech Media contacts:

    Katja Stout, Scius Communications (EU)

    Direct: +44 (0) 7789435990

    Email: 

    Ryo Imai / Robert Flamm, Ph.D. (US), Burns McClellan, Inc.

    212-213-0006 ext. 315 / 364

    Email: 

    Henry Hodge, Vaccitech

    Direct: +44 (0) 7533 421 442

    Email: 



    Primary Logo

    View Full Article Hide Full Article
  2. OXFORD, United Kingdom, April 29, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc ("Vaccitech") (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the pricing of its initial public offering in the United States of 6,500,000 American Depositary Shares ("ADSs") representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS for total gross proceeds of $110.5 million. All ADSs sold in the offering are being offered by Vaccitech. The ADSs are expected to begin trading on The Nasdaq Global Market on April 30, 2021 under the ticker symbol "VACC."  In addition…

    OXFORD, United Kingdom, April 29, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc ("Vaccitech") (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the pricing of its initial public offering in the United States of 6,500,000 American Depositary Shares ("ADSs") representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS for total gross proceeds of $110.5 million. All ADSs sold in the offering are being offered by Vaccitech. The ADSs are expected to begin trading on The Nasdaq Global Market on April 30, 2021 under the ticker symbol "VACC."  In addition, Vaccitech has granted the underwriters a 30-day option to purchase up to an additional 975,000 ADSs at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on May 4, 2021, subject to satisfaction of customary closing conditions.

    Morgan Stanley, Jefferies, Barclays and William Blair are acting as book-runners for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.

    A registration statement on Form S-1 relating to these securities was declared effective on April 29, 2021. The securities referred to in this announcement are being offered only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at ; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at ; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at  or telephone at 1-888-603-5847; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Vaccitech plc

    Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company's proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable safety profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

    Vaccitech Media contacts:

    Katja Stout, Scius Communications (EU)

    Direct: +44 (0) 7789435990

    Email: 

    Ryo Imai / Robert Flamm, Ph.D. (US), Burns McClellan, Inc.

    212-213-0006 ext. 315 / 364

    Email:  / 

    Henry Hodge, Vaccitech

    Direct: +44 (0) 7533 421 442

    Email: 



    Primary Logo

    View Full Article Hide Full Article
View All Vaccitech plc News